Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience

ABSTRACT The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders. Methods: Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant. Results: Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group. Conclusion: Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.

Download Full-text

The use of onabotulinum toxin A (Botox®) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study

Neurological Sciences ◽

10.1007/s10072-016-2568-z ◽

2016 ◽

Vol 37 (7) ◽

pp. 1127-1131 ◽

Cited By ~ 29

Author(s):

Marco Russo ◽

Gian Camillo Manzoni ◽

Arens Taga ◽

Antonio Genovese ◽

Licia Veronesi ◽

...

Keyword(s):

Observational Study ◽

Chronic Migraine ◽

Prospective Observational Study ◽

Toxin A ◽

Headache Centre ◽

Onabotulinum Toxin A

Download Full-text

A case of migraine treatment in a patient with a clinical diagnosis of CHARGE syndrome using onabotulinum toxin A

American Journal of Medical Genetics Part A ◽

10.1002/ajmg.a.62340 ◽

2021 ◽

Author(s):

Julia B. Morrison ◽

Bradley M. Fisher ◽

Angela Arra ◽

Michael Bezuhly ◽

Kim Blake

Keyword(s):

Clinical Diagnosis ◽

Charge Syndrome ◽

Migraine Treatment ◽

Toxin A ◽

Onabotulinum Toxin A

Download Full-text

The Effect of Adding Calcitonin Gene-Related Peptide Monoclonal Antibodies to Onabotulinum Toxin A Therapy on Headache Burden: A Retrospective Observational Study

10.21203/rs.2.22760/v1 ◽

2020 ◽

Author(s):

Seniha Ozudogru ◽

Jared Bartell ◽

Heidi Yuan ◽

Kathleen Digre ◽

Susan Baggaley

Keyword(s):

Monoclonal Antibodies ◽

Chronic Migraine ◽

Treatment Options ◽

Calcitonin Gene Related Peptide ◽

Toxin A ◽

Beneficial Effects ◽

Related Peptide ◽

C Fibers ◽

Calcitonin Gene ◽

Onabotulinum Toxin A

Abstract Background The calcitonin gene-related peptide monoclonal antibody medications represent a novel and effective group of treatment options that can be added on to existing regimens such as onabotulinum toxin A injections for the treatment of refractory chronic migraine. Mechanistically, calcitonin gene-related peptide antibodies have been shown to inhibit Aδ fibers while onabotulinum toxin A modulates C fibers. Due to the differing loci of effect and anecdotal observations, a synergistic effect between these therapies is a theoretical possibility. The aim of this study was to investigate this relationship. Methods Patients from the University of Utah Headache Clinic having received at least two rounds of injections of onabotulinum toxin A who responded partially but not completely to therapy were started on a calcitonin gene-related peptide antibody medication. The patients’ responses to a brief headache burden questionnaire prior to their onabotulinum toxin A administration at the time of each visit were collected. Parameters we monitored included the number of headaches experienced while receiving onabotulinum toxin A therapy, the initial timing of the of the wear off period, and the number of headaches after that the wear off period began. Results Half of the 36 patients included in the study demonstrated an improvement in their headache burden based on at least one parameter from their questionnaire. These 18 patients reported an average increase of 2.0 additional weeks for the beneficial effects of the onabotulinum toxin A to wear off. Twelve patients reported no change in onabotulinum toxin A efficacy while 6 patients showed greater headache burden or lower onabotulinum toxin A treatment efficacy following the initiation of one of the monoclonal antibodies. Conclusions Our study highlights the potential of calcitonin gene-related peptide monoclonal antibodies to serve as an effective add-on therapy for chronic migraine patients receiving onabotulinum toxin A injections, especially those designated “responders” but still experiencing the drug wear off prior to the next round of injections. Larger sample sizes and more frequent at-home questionnaire data are needed to corroborate these results.

Download Full-text

Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin A

European Neurology ◽

10.1159/000509853 ◽

2020 ◽

Vol 83 (5) ◽

pp. 517-522

Author(s):

Yesim Beckmann ◽

Fatma Çetin Üncü ◽

Tülay Kurt İncesu ◽

Sabiha Türe

Keyword(s):

Quality Of Life ◽

Adverse Events ◽

Chronic Migraine ◽

Well Being ◽

Health Related Quality ◽

Toxin A ◽

Onabotulinum Toxin A ◽

Related Quality ◽

Health Related

Objective: The present study aims to describe the efficacy and safety of onabotulinum toxin A (BonT-A) with evaluation of treatment satisfaction and impact on quality of life in chronic migraine (CM) patients in real life. Methods: This study was conducted in CM patients who were treated with BoNT-A with 12 months of follow-up. Data about outcome, adverse events, and patients’ pre- and post-treatment status including health-related quality of life data were analyzed. Health-related quality of life scores were measured at baseline and months 6 and 12 after the beginning of BoNT-A administration. Results: Of 42 enrolled patients, 30 were included in the analysis. At 12 months, all patients showed a reduction in number of headaches and analgesic use per month and none reported adverse events. After BoNT-A supplementation, health-related quality-of-life scores improved significantly. There was a direct association between health-related quality of life with reduction of headache days at the end of study. Conclusion: This study confirms that BoNT-A treatment is effective on CM and improves the functional well-being and quality of life of patients.

Download Full-text